p class=text>With an eye on penetrating the diagnostic sector, therapeutics firm Ribozyme Pharmaceuticals Inc. reached a deal with a major Japanese company.

Ribozyme entered into an agreement with Fujirebio Inc. to develop and commercialize ribozyme-based clinical diagnostic products, marking the first significant union between Ribozyme and its allosteric ribozyme platform technology with a diagnostics company.

p class=text>With an eye on penetrating the diagnostic sector, therapeutics firm Ribozyme Pharmaceuticals Inc. reached a deal with a major Japanese company.Ribozyme entered into an agreement with Fujirebio Inc. to develop and commercialize ribozyme-based clinical diagnostic products, marking the first significant union between Ribozyme and its allosteric ribozyme platform technology with a diagnostics company.